Resources
10 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 11/27/2019 (updated 3/28/2024)
This guide is aimed at people who inject drugs to help reduce some of the problems caused by injecting.
Posted 10/12/2020 (updated 3/29/2024)
This report summarizes current (as of 2011) guidelines or recommendations published by multiple agencies of the U.S. Department of Health and Human Services (DHHS) for prevention and control of human immunodeficiency virus (HIV) infection, viral hepatitis, sexually transmitted diseases (STDs), and tuberculosis (TB) for persons who use drugs illicitly.
Posted 1/27/2021 (updated 4/4/2024)
The current study examined the accuracy of sensory discernment strategies by measuring study participants’ descriptions of the last opioid injected and checked with a fentanyl test strip (FTS) by that test's positive/negative result. The primary objective was to determine associations between FTS results and descriptions of the illi it opioid's physical appearance and physiological effects.
Posted 3/10/2021 (updated 4/5/2024)
The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic groups, including organized violent gangs, serve in domestic drug trafficking. The most widely trafficked drugs are discussed in terms of their availability, consumption and overdose related deaths, production and cultivation, transportation, and distribution.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 2/16/2022 (updated 3/26/2024)
In the United States, combined stimulant/opioid overdose mortality has risen dramatically over the last decade. These increases may particularly affect non-Hispanic Black and Hispanic populations. We used death certificate data from the US National Center for Health Statistics (2007–2019) to compare state-level trends in overdose mortality due to opioids in combination with 1) cocaine and 2) methamphetamine and other stimulants (MOS) across racial/ethnic groups (non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic Asian American/Pacific Islander).
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).
Posted 8/23/2022 (updated 3/27/2024)
In this cross-sectional, multistate study of rural communities, 79% of people using drugs reported past-30-day methamphetamine use; nonfatal overdose was greatest in people using both methamphetamine and opioids (22%) vs opioids alone (14%), or methamphetamine alone (6%). People using both substances reported the least access to treatment; only 17% of those using methamphetamine alone had naloxone.
Posted 11/1/2022 (updated 3/27/2024)
The webinar held by NASTAD on October 26, 2022, 4:00-5:30pm featured a dynamic discussion on integrating harm reduction principles and practices, including naloxone distribution, safe disposal, and harm reduction supply access, within the community health care setting. Health centers across the country that offer these services as part of comprehensive care shared their experiences and the ways that service expansion can contribute to engagement and care access.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.